| 74.11 -2.29 (-3%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 94.41 | 1-year : | 102.58 |
| Resists | First : | 80.83 | Second : | 87.83 |
| Pivot price | 81.33 |
|||
| Supports | First : | 69.51 | Second : | 57.83 |
| MAs | MA(5) : | 81.44 |
MA(20) : | 80.55 |
| MA(100) : | 70.47 |
MA(250) : | 53.93 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 26.4 |
D(3) : | 53.1 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 87.83 | Low : | 14.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ARWR ] has closed below the lower bollinger band by 1.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ARWR ] is to continue within current trading range. Bollinger Bands are 29.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 75 - 75.53 | 75.53 - 75.93 |
| Low: | 71.3 - 72 | 72 - 72.55 |
| Close: | 73.12 - 74.09 | 74.09 - 74.83 |
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Fri, 10 Jul 2026
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Fri, 10 Jul 2026
Arrowhead Pharmaceuticals (ARWR) Is Up 6.6% After Russell Index Upgrade Has The Bull Case Changed? - Sahm
Fri, 10 Jul 2026
Arrowhead Pharmaceuticals Slides as Investors Appear to Take Profits After Recent Catalyst-Driven Run - Quiver Quantitative
Fri, 10 Jul 2026
Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send? - TradingKey
Thu, 09 Jul 2026
Arrowhead Pharmaceuticals (ARWR) Q4 2025 earnings summary - Quartr
Thu, 09 Jul 2026
Arrowhead Pharmaceuticals (ARWR) Q2 2025 earnings summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 141 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 88.7 (%) |
| Shares Short | 8,430 (K) |
| Shares Short P.Month | 12,390 (K) |
| EPS | -2.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.36 |
| Profit Margin | -48.4 % |
| Operating Margin | -191.6 % |
| Return on Assets (ttm) | -7.3 % |
| Return on Equity (ttm) | -42.4 % |
| Qtrly Rev. Growth | -86.5 % |
| Gross Profit (p.s.) | 4.41 |
| Sales Per Share | 4.41 |
| EBITDA (p.s.) | -1.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -32.65 |
| PEG Ratio | 0 |
| Price to Book value | 16.95 |
| Price to Sales | 16.78 |
| Price to Cash Flow | -287.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|